Eli Lilly’s $449 Zepbound play: new “Employer Connect” targets workplace coverage gap
Eli Lilly launched “Employer Connect” to let U.S. employers offer its obesity drug Zepbound at network pharmacies for $449 per dose. Partners include GoodRx, Teladoc Health, and Mark Cuban Cost Plus Drug Company. Lilly shares fell about 2% after the announcement. The company said final out-of-pocket costs will depend on each employer’s cost-sharing model.